These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8612015)

  • 21. Progress towards the development of malaria vaccines.
    Malkin E; Dubovsky F; Moree M
    Trends Parasitol; 2006 Jul; 22(7):292-5. PubMed ID: 16707275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.
    Lalvani A; Moris P; Voss G; Pathan AA; Kester KE; Brookes R; Lee E; Koutsoukos M; Plebanski M; Delchambre M; Flanagan KL; Carton C; Slaoui M; Van Hoecke C; Ballou WR; Hill AV; Cohen J
    J Infect Dis; 1999 Nov; 180(5):1656-64. PubMed ID: 10515829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.
    Prieur E; Gilbert SC; Schneider J; Moore AC; Sheu EG; Goonetilleke N; Robson KJ; Hill AV
    Proc Natl Acad Sci U S A; 2004 Jan; 101(1):290-5. PubMed ID: 14694197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune protection-inducing protein structures (IMPIPS) against malaria: the weapons needed for beating Odysseus.
    Patarroyo ME; Patarroyo MA; Pabón L; Curtidor H; Poloche LA
    Vaccine; 2015 Dec; 33(52):7525-37. PubMed ID: 26469723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.
    Heppner DG; Kester KE; Ockenhouse CF; Tornieporth N; Ofori O; Lyon JA; Stewart VA; Dubois P; Lanar DE; Krzych U; Moris P; Angov E; Cummings JF; Leach A; Hall BT; Dutta S; Schwenk R; Hillier C; Barbosa A; Ware LA; Nair L; Darko CA; Withers MR; Ogutu B; Polhemus ME; Fukuda M; Pichyangkul S; Gettyacamin M; Diggs C; Soisson L; Milman J; Dubois MC; Garçon N; Tucker K; Wittes J; Plowe CV; Thera MA; Duombo OK; Pau MG; Goudsmit J; Ballou WR; Cohen J
    Vaccine; 2005 Mar; 23(17-18):2243-50. PubMed ID: 15755604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccines for preventing malaria.
    Graves P; Gelband H
    Cochrane Database Syst Rev; 2000; (2):CD000129. PubMed ID: 10796492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children.
    Trape JF; Rogier C
    Lancet; 1995 Jan; 345(8942):134-5. PubMed ID: 7815878
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
    Moorthy VS; Pinder M; Reece WH; Watkins K; Atabani S; Hannan C; Bojang K; McAdam KP; Schneider J; Gilbert S; Hill AV
    J Infect Dis; 2003 Oct; 188(8):1239-44. PubMed ID: 14551895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SPf66 vaccine trial in Brazil: conceptual framework study design and analytical approach.
    Urdaneta M; Prata A; Struchiner CJ; Tosta CE; Tauil P; Boulos M
    Rev Soc Bras Med Trop; 1996; 29(3):259-69. PubMed ID: 8701046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An efficacy trial of the malaria vaccine SPf66 in Gambian infants--second year of follow-up.
    Bojang KA; Obaro SK; D'Alessandro U; Bennett S; Langerock P; Targett GA; Greenwood BM
    Vaccine; 1998 Jan; 16(1):62-7. PubMed ID: 9607010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serious setback for Patarroyo vaccine.
    Marshall E
    Science; 1996 Sep; 273(5282):1652. PubMed ID: 8830407
    [No Abstract]   [Full Text] [Related]  

  • 32. Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum.
    Alonso PL; Smith TA; Armstrong-Schellenberg JR; Kitua AY; Masanja H; Hayes R; Hurt N; Font F; Menendez C; Kilama WL; Tanner M
    J Infect Dis; 1996 Aug; 174(2):367-72. PubMed ID: 8699068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of SPf(66)n: a chimeric molecule used as a malaria vaccine.
    López MC; Silva Y; Thomas MC; Garcia A; Faus MJ; Alonso P; Martinez F; Del Real G; Alonso C
    Vaccine; 1994 May; 12(7):585-91. PubMed ID: 8085374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malaria vaccine trials: SPf66 and all that.
    Riley E
    Curr Opin Immunol; 1995 Oct; 7(5):612-6. PubMed ID: 8573301
    [No Abstract]   [Full Text] [Related]  

  • 35. Chromatographic characterization of synthetic peptides: SPf66 malaria vaccine.
    Santoveña A; Oliva A; Guzman F; Patarroyo ME; Llabrés M; Fariña JB
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Jan; 766(1):3-12. PubMed ID: 11820294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety evaluation of SPf66 malaria vaccine in Brazil.
    Urdaneta M; Prata A; Struchiner CJ; Tosta CE; Tauil P; Boulos M
    Rev Soc Bras Med Trop; 1996; 29(5):497-501. PubMed ID: 8885674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tough test for malaria vaccine.
    White NJ
    Lancet; 1994 Oct; 344(8931):1172-3. PubMed ID: 7934534
    [No Abstract]   [Full Text] [Related]  

  • 38. Stability indicating method for SPf66 antimalarial peptide in solution.
    Santoveña A; Dorta MJ; Oliva A; Llabrés M; Patarroyo ME; Fariña JB
    Drug Dev Ind Pharm; 2004 Apr; 30(4):389-95. PubMed ID: 15132181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new site of attack for a malaria vaccine.
    Draper SJ; Higgins MK
    Nat Med; 2018 Apr; 24(4):382-383. PubMed ID: 29634679
    [No Abstract]   [Full Text] [Related]  

  • 40. First malaria vaccine to be tested in pilot projects, WHO announces.
    Gulland A
    BMJ; 2016 Nov; 355():i6212. PubMed ID: 27872043
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.